

## Only 6 weeks to go until The Transdermal and Microneedle Delivery Conference

SMi Reports: Time is running out to Register for SM's inaugural conference: Transdermal and Microneedle Delivery will take place on 24th - 25th January 2022

LONDON, LONDON, UNITED KINGDOM, December 2, 2021 /EINPresswire.com/ -- SMi Group is proud to present the inaugural Transdermal and Microneedle Drug Delivery Conference, taking place on the 24th to 25th January 2022, in



London, UK. The Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in the latest innovations in device design and formulation with case studies from thought leaders.



With only 6 weeks to go until the conference tickets are selling fast for the first event of its kind in the UK and Europe. "

> Richard Jones, Conference Manager

The conference will also consider key developments in the transdermal drug delivery field, including the innovations in microneedle technology for a COVID-19 vaccine and opportunities for development in cancer vaccine delivery, advances in microarray patches, and microneedle-based diagnostics. Key regulatory updates including guidance on classification of microneedle devices and considerations for ensuring quality will be presented by regulatory experts for a comprehensive outlook of this exciting and evergrowing field, and the importance of considering human

factors in order to enhance the user experience will be presented by industry experts.

This two-day agenda offers you peer-to-peer networking with leaders in <u>transdermal and microneedle delivery</u>. Visit the website here: <u>http://transdermal-microneedle-delivery.co.uk/einnews</u>

Sponsors of the conference include: LTS Lohmann Therapie-Systeme AG, QuadMedicine

SMi Group offer direct access to key decision makers through tailored sponsorship and exhibitor packages. For details contact Alia Malick, Director on +44 (0)20 7827 6168 or email amalick@smionline.co.uk

## Key Benefits of Attending Include:

- •Gain insight into developments in microneedles for drug delivery and diagnostics
- •Hear key regulatory updates from regulatory bodies including FDA and WHO on guidance for regulatory compliance
- •Explore new applications of microneedle technology in vaccinations
- •Discover advances in design and application of transdermal patches
- •Explore and benchmark against industry developments through case studies and real-world examples in device development for microneedles

## Featured Regulatory Speakers:

- Caroline Strasinger, Master Reviewer, Office of Pharmaceuticals Quality, CDER/FDA
- •Bridgitte Giersing, Team Lead, Vaccine Prioritization and Platforms, World Health Organisation

## Featured 2022 Speakers Include:

- •Marion Menozzi-Arnaud, Senior Specialist, Market Shaping, Gavi, The Vaccine Alliance
- •Hayley Lewis, Senior Vice President, Zosano Pharma
- •Courtney Jarrahian, Program Advisor, PATH
- •Michael Schrader, CEO, Vaxess Technologies, Inc.
- •Illemens Guenther, Director of Senior Expert Nonclinical Safety, Bayer AG
- •James Birchall, Professor of Pharmaceutical Sciences and Deputy Head of School, Cardiff University

Transdermal and Microneedle Delivery 24-25 January 2022 London, UK

http://transdermal-microneedle-delivery.co.uk/einnews

#SMiTransdermal

For media enquiries contact Richard Jones on Tel: +44 (0)20 7827 6088 / Email: rjones@smionline.co.uk

--- ENDS -

Richard Edward Jones SMi Group +44 20 7827 6088 email us here This press release can be viewed online at: https://www.einpresswire.com/article/557404474

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.